Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Amgen (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 131,871,936
  • Shares Outstanding, K 735,400
  • Annual Sales, $ 22,991 M
  • Annual Income, $ 7,722 M
  • 36-Month Beta 1.36
  • Price/Sales 5.73
  • Price/Cash Flow 12.24
  • Price/Book 4.30

Price Performance

See More
Period Period Low Period High Performance
1-Month
166.36 +7.79%
on 06/21/17
180.73 -0.78%
on 07/20/17
+13.03 (+7.84%)
since 06/20/17
3-Month
152.16 +17.85%
on 05/23/17
180.73 -0.78%
on 07/20/17
+17.28 (+10.66%)
since 04/20/17
52-Week
133.64 +34.18%
on 11/04/16
184.21 -2.65%
on 03/15/17
+16.07 (+9.84%)
since 07/20/16

Most Recent Stories

More News
Amgen Inc (AMGN) Crosses Pivot Point Resistance at $178.03

Shares of Amgen Inc (NASDAQ:AMGN) opened today above their pivot of $177.08 and have already reached the first level of resistance at $178.03. Should the shares continue to rise, the resistance pivots...

AMGN : 179.32 (+0.08%)
Biotech Stock Roundup: Vertex Boosted by CF Data, FDA Nod for Gilead, Puma Drugs

Vertex (VRTX) got a significant boost with positive data from its cystic fibrosis (CF) pipeline while quite a few companies provided regulatory updates.

SRPT : 40.93 (+20.10%)
PBYI : 94.75 (-0.94%)
VRTX : 159.33 (-0.23%)
GILD : 73.42 (+0.96%)
AMGN : 179.32 (+0.08%)
ALXN : 129.81 (+1.97%)
BIIB : 281.44 (-0.18%)
Ligand Signs Agreement with Amgen, Grants Rights to Captisol

Ligand Pharmaceuticals Incorporated (LGND) announced that it has signed a commercial license and supply agreement with Amgen Inc. granting exclusive worldwide rights to use Ligand's Captisol technology...

LGND : 120.69 (+0.17%)
MRK : 62.94 (+0.51%)
NVS : 85.42 (+0.46%)
AMGN : 179.32 (+0.08%)
Novartis Tops Q2 Earnings, Sandoz Faces Pricing Pressure

Novartis AG (NVS) reported second-quarter 2017 core earnings of $1.22 per share, beating the Zacks Consensus Estimate of $1.16 but the recorded figure was a penny lower than the year-ago figure of $1.23....

JNJ : 136.57 (+1.01%)
NVS : 85.42 (+0.46%)
RHHBY : 32.2000 (+0.75%)
AMGN : 179.32 (+0.08%)
Amgen And Array BioPharma Announce Preclinical License And Collaboration Agreement In Inflammation

Amgen (NASDAQ:AMGN) and Array BioPharma (NASDAQ:ARRY) today announced a collaboration agreement for the discovery and development of novel drugs for autoimmune disorders. The undisclosed target and lead...

ARRY : 8.38 (-1.06%)
AMGN : 179.32 (+0.08%)
Featured Company News - Amgen Submits Regulatory Applications in US, Europe to Include Overall Survival Data in KYPROLIS Label

Research Desk Line-up: Peregrine Pharma Post Earnings Coverage

PPHM : 5.22 (+0.38%)
AMGN : 179.32 (+0.08%)
Why Did Radius Health (RDUS) Stock Plummet Today?

Shares of Radius Health (RDUS) dropped more than 7.8% in early morning trading hours Monday after the company announced that Jesper Hoiland, a former top-ranking executive at Novo Nordisk (NVO), has been...

NVO : 43.55 (+2.30%)
RDUS : 42.34 (-0.28%)
LLY : 84.75 (+0.62%)
AMGN : 179.32 (+0.08%)
Mylan's Biosimilar Herceptin Gets FDA Advisory Committee Nod

Mylan N.V. (MYL) and partner, Biocon Ltd. announced that the FDA Oncologic Drugs Advisory Committee (ODAC) unanimously recommended approval of its biosimilar version of Roche's (RHHBY) breast cancer drug...

MYL : 39.49 (+3.00%)
AGN : 249.07 (+1.08%)
RHHBY : 32.2000 (+0.75%)
AMGN : 179.32 (+0.08%)
Amgen (AMGN) Gets CRL for Osteoporosis Drug Evenity's BLA

Amgen Inc. (AMGN) and partner UCB SA (UCBJF) announced that the FDA has issued a complete response letter (CRL) for the biologics license application (BLA) for Evenity (romosozumab).

CELG : 136.31 (+0.97%)
MRK : 62.94 (+0.51%)
AMGN : 179.32 (+0.08%)
UCBJF : 69.2000 (+0.79%)
Ligand Enters Into Commercial License and Supply Agreement with Amgen for Rights to Use Captisol in the Formulation of AMG 330

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has entered into a commercial license and supply agreement with Amgen, granting rights to use Ligand's Captisol...

LGND : 120.69 (+0.17%)
AMGN : 179.32 (+0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Support & Resistance

2nd Resistance Point 181.49
1st Resistance Point 180.41
Last Price 179.32
1st Support Level 178.56
2nd Support Level 177.79

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.